The National Institutes of Health (NIH), a part of the U.S. Department of Health and Human Services, is the nation’s medical research agency — making important discoveries that improve health and save lives.
The goal of this Funding Opportunity Announcement (FOA) is to expedite the development of medications for Substance Use Disorders (SUDs). It seeks to fund a variety of preclinical and/or clinical research projects aimed at advancing medications closer to FDA approval. The grant emphasizes funding for high-impact studies that can quickly yield essential results. These U01s are expected to be short-term, funded for up to 3 years with grants as large as $5 million per year, involving cooperative agreements with significant NIDA staff involvement to enable critical medication development studies not feasible with traditional R01 activity codes.